
Description: Europe Continuous Glucose Monitoring Systems Market by Component (Sensors, Transmitters & Receivers, and Integrated Insulin Pumps), Demographics (Child Population (≤14 years), and Adult Population (>14 years)), and End User (Diagnostic Centers/Clinics, ICUs, and Home Healthcare) - Global Opportunity Analysis and Industry Forecast, 2014-2022.

Continuous glucose monitoring (CGM) is a latest technological advancement in the field of diabetes management. CGM system is a type of device that monitors glucose by a biosensor, which is inserted through the transcutaneous or subcutaneous route. This embedded sensor measures glucose levels in interstitial fluid or blood, and transmits the information using a transmitter to a receiver/monitor to display the results. The use of CGM systems is crucial to avoid diabetic complications, as this technology can be used to periodically monitor the glucose levels. Therefore, glucose monitoring device manufacturing companies focus on the development of novel and technologically advanced CGMS. It offers a wide range of applications for all age cohorts, healthcare settings (diagnostic centers/clinics, hospital ICUs, and home healthcare), and geographies. Thus, CGMS market poses lucrative opportunities for both CGMS manufacturers and insulin pump manufacturers.

The European CGMS market generated $58 million in 2015, and is projected to reach $792 million by 2022, expanding at a CAGR of 44.9% during the forecast period. High-tech CGMS devices, such as wearable & smartphone-connected CGMS, non-invasive CGMS, smartphone-connected CGMS, and “smart” diabetes management solution (also called artificial/bionic pancreas), are expected to result in higher adoption of CGMS among endocrinologists and patients.

The market is categorized based on component, demographics, end user, and country. The component segment includes durable components such as transmitters & receivers and integrated insulin pumps; and disposable components such as sensors. Sensors occupy a dominant share in the European CGMS market owing to short life span of these devices, recurring sales of CGMS, and bulk purchases. Therefore, they are deployed in diagnostic centers/clinics. Moreover, the adoption of CGMS in hospital ICUs and in-home healthcare settings has increased in recent years. End users of CGMS devices are diabetic patients, categorized into child population (=14 years) and adult population (>14 years).

The report includes comprehensive analysis and segmentation of different countries in Europe, including UK, France, Germany, Spain, Italy, the Netherlands, Norway, Sweden, Denmark, Finland, and rest of Europe.

Major strategies adopted by market players are collaborations, product launches, and product approvals. Agreement/partnership strategy by companies enables greater focus on innovation, distribution, and commercialization of devices. For instance, in 2016, Senseonics signed an agreement with Roche to commercialize Senseonics’ Eversense continuous glucose monitoring system. Under this agreement, Roche can sell its CGM systems in Germany, Italy, and the Netherlands.

KEY MARKET BENEFITS

In-depth and country-level analysis provides the current trends and future estimations in the European CGMS market from 2014 to 2022, which would enable stakeholders to capitalize on the prevailing market opportunities. Comprehensive analysis of factors that drive and restrict the growth of the market is provided. In-depth analysis of current research and clinical developments within the European CGMS market is provided along with the key dynamic factors. The key players in the European CGMS market are profiled, along with their development strategies, to understand the competitive outlook.

KEY MARKET SEGMENTS:
By Component

Sensors
Transmitters & Receivers
Integrated Insulin Pumps

By Demographics

Child Population (=14 years)
Adult Population (>14 years)

By End User

Diagnostics/Clinics
ICUs
Home Healthcare

By Country

UK
Germany
France
Spain
Italy
The Netherlands
Norway
Sweden
Denmark
Finland
Rest of Europe

Contents:
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION
3.2. NEED FOR GlUCOSE MONITORING SYSTEMS
3.2.1. Diabetesa pandemic
3.2.1.1. Type 1 diabetes
3.2.1.2. Type-2 diabetes
3.2.1.3. Prediabetes and gestational diabetes mellitus (GDM)
3.2.1.4. Gestational diabetes mellitus (GDM)
3.2.1.5. Secondary diabetes
3.2.1.6. Global healthcare expenditure on diabetes
3.3. TECHNOLOGICAL ADVANCEMENTS IN CGMS
3.3.1. Smartphone-connected CGMS
3.3.1.1 Wearable and smartphone-connected CGMS
3.3.1.2. 'Smart diabetes management solutionbionic/artificial pancreas
3.3.1.3. Non-invasive CGMS
3.3.1.4. Invasive CGMS
3.3.2. CGMS: PRIME END USER SEGMENTS
3.3.2.1. CGMS: role in intensive care units (ICUs)
   3.3.2.1.1. Stress hyperglycemia: common occurrence in ICUs
   3.3.2.2. Non-standardization and erroneous glycemic control across ICUs
   3.3.2.3. Benefits and driving factors of CGMS in ICUs
      3.3.2.3.1. Use of CGMS for tight glycemic control in ICUs
      3.3.2.3.2. Cost benefits due to use of CGMS
      3.3.2.3.3. Lower effectiveness of POC glucometers than CGMS in ICUs
      3.3.2.3.4. CGMS: most preferred by ICU staff
3.4. KEY FINDINGS
   3.4.1. Top investment pockets
   3.4.1.1. CGMS market, by components
   3.4.2. Top winning strategies
3.5. PATENT ANALYSIS
3.6. MARKET SHARE ANALYSIS, 2015
3.7. GOVERNMENT REGULATIONS
      3.7.1.1. Objective and Scope of ISO 13485:2003
3.8. EUROPE REIMBURSEMENT SCENARIO
   3.8.1. Germany
   3.8.2. France
   3.8.3. UK
   3.8.4. Spain
   3.8.5. Italy
3.9. MARKET DYNAMICS
   3.9.1. Drivers
      3.9.1.1. Benefits of CGMS over POC glucometers
      3.9.1.2. Rise in incidence of diabetes cases
      3.9.1.3. Technological advancements
   3.9.2. Restraints
      3.9.2.1. Adverse effects and accuracy
      3.9.2.2. Reimbursement and stringent regulatory issues
   3.9.3. Opportunities
      3.9.3.1. High adoption rate of CGMS in home healthcare and ICUs
      3.9.3.2. Increase in product awareness
      3.9.3.3. High undiagnosed patient population

CHAPTER 4 EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS
4.1. OVERVIEW
   4.1.1. Market size and forecast
4.2. SENSORS
   4.2.1. Key market trends
   4.2.2. Key growth factors and opportunities
   4.2.3. Market size and forecast
4.3. TRANSMITTERS & RECEIVERS
   4.3.1. Key market trends
   4.3.2. Key growth factors and opportunities
   4.3.3. Market size and forecast
4.4. INTEGRATED INSULIN PUMPS
   4.4.1. Key market trends
   4.4.2. Key growth factors and opportunities
   4.4.3. Market size and forecast

CHAPTER 5 EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET BY DEMOGRAPHICS
5.1. OVERVIEW
   5.1.1. Market size and forecast
5.2. ADULT POPULATION (>14 YEARS)
   5.2.1. Market size and forecast
5.3. CHILDREN POPULATION (14 YEARS)
   5.3.1. Market size and forecast
CHAPTER 6 EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER

6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. DIAGNOSTIC CENTERS/CLINICS
6.2.1. Market size and forecast
6.3. ICUS
6.3.1. Market size and forecast
6.4. HOME HEALTHCARE
6.4.1. Market size and forecast

CHAPTER 7 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY

7.1. OVERVIEW
7.1.1. Key market trends
7.1.2. Key growth factors and opportunities
7.1.3. Market size and forecast
7.1.4. Germany
7.1.4.1. Market size and forecast
7.1.5. France
7.1.5.1. Market size and forecast
7.1.6. UK
7.1.6.1. Market size and forecast
7.1.7. Spain
7.1.7.1. Market size and forecast
7.1.8. Italy
7.1.8.1. Market size and forecast
7.1.9. Norway
7.1.9.1. Market size and forecast
7.1.10. Sweden
7.1.10.1. Market size and forecast
7.1.11. Denmark
7.1.11.1. Market size and forecast
7.1.12. Finland
7.1.12.1. Market size and forecast
7.1.13. Netherlands
7.1.13.1. Market size and forecast
7.1.14. Rest of Europe
7.1.14.1. Market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. ABBOTT LABORATORIES
8.1.1. Overview
8.1.2. Operating business segments
8.1.3. Business performance
8.1.4. Key strategic moves and developments

8.2. DEXCOM, INC.
8.2.1. Overview
8.2.2. Business performance
8.2.3. Key strategic moves and developments

8.3. ECHO THERAPEUTICS, INC.
8.3.1. Overview
8.3.2. Business performance
8.3.3. Key strategic moves and developments

8.4. F. HOFFMANN-LA ROCHE LTD.
8.4.1. Overview
8.4.2. Business performance
8.4.3. Key strategic moves and developments

8.5. INSULET CORPORATION
8.5.1. Overview
8.5.2. Business performance
8.5.3. Key strategic moves and developments
8.6. JOHNSON & JOHNSON
8.6.1. Overview
8.6.2. Operating business segments
8.6.3. Business performance
8.6.4. Key strategic moves and developments
8.7. MEDTRONIC PLC
8.7.1. Overview
8.7.2. Operating business segments
8.7.3. Business performance
8.7.4. Key strategic moves and developments
8.8. SENSEONICS HOLDINGS, INC.
8.8.1. Overview
8.8.2. Key strategic moves and developments

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/4033344/](http://www.researchandmarkets.com/reports/4033344/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Web Address: http://www.researchandmarkets.com/reports/4033344/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Single User</th>
<th>1 - 5 Users</th>
<th>Enterprisewide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 5370</td>
<td>USD 5910</td>
<td>USD 7800</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Account number</td>
<td>833 130 83</td>
</tr>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
</tbody>
</table>
| Bank Address      | Ulster Bank,
                   | 27-35 Main Street,
                   | Blackrock,
                   | Co. Dublin,
                   | Ireland.            |

If you have a Marketing Code please enter it below:

Marketing Code: ________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World